X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
P2B001 showed superior efficacy to each of its individual components in the trial and comparable efficacy to marketed doses of Pramipexole ER, but with reduced adverse events related to dopaminergic side effects and sleepiness, and with less worsening on the ESS.
Lead Product(s): Pramipexole Dihydrochloride,Rasagiline Mesylate
Therapeutic Area: Neurology Product Name: P2B001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2022
Details:
Results demonstrated that P2B001, a combination of dopamine agonist, pramipexole, and MAO-B inhibitor, rasagiline has symptomatic benefits comparable to higher doses of marketed pramipexole ER, yet with less dopaminergic side effects and significantly less daytime sleepiness.
Lead Product(s): Pramipexole Dihydrochloride,Rasagiline Mesylate
Therapeutic Area: Neurology Product Name: P2B001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
Details:
Results demonstrate P2B001 (pramipexole) distinctive combination of efficacy and enhanced safety, supporting its potential as a first-line treatment option for people with early PD.
Lead Product(s): Pramipexole Dihydrochloride,Rasagiline Mesylate
Therapeutic Area: Neurology Product Name: P2B001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2022
Details:
Under the terms of the agreement, Myung In Pharm will seek regulatory approval for P2B001 in South Korea and will manufacture, commercialize and distribute P2B001 in the region.
Lead Product(s): Pramipexole Dihydrochloride,Rasagiline Mesylate
Therapeutic Area: Neurology Product Name: P2B001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Myung In Pharm
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 18, 2021
Details:
The proceeds will support Phase 3 pivotal trials for CTC-501 for the treatment of Major Depressive Disorder (MDD) and CTC-413 for the treatment of Parkinson’s Disease (PD) as well as completion of the development and validation of a diagnostic product for Parkinson’s Disease.
Lead Product(s): Pramipexole Dihydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: CTC-501
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Chinalink Asia Holdings
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing October 20, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
